secwatch.observer — SEC 8-K summary
======================================

Issuer:     GRI Bio, Inc. (GRI)
CIK:        0001824293
Form:       8-K
Filed at:   2022-04-22T23:59:59+00:00
Accession:  0001824293-22-000024
Event type: other_material
Sentiment:  negative
Materiality: 0.70
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vallon Pharmaceuticals eliminates SVP role, hires Ladenburg for strategic review to maximize value
--------------------------------------------------------------------------------

- Effective April 19, 2022, eliminated Penny Toren's SVP Regulatory Affairs position; no disagreement or cause; 6-month severance.
- Engaged Ladenburg Thalmann to evaluate strategic alternatives including merger, business combination, or asset sale.
- Clinical-stage biopharma focused on abuse-deterrent ADHD drugs ADAIR and ADMIR; cash preservation via streamlining.
- No assurance any transaction will result; company will not disclose details unless a specific deal is reached.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1824293/000182429322000024/0001824293-22-000024-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1824293/000182429322000024/ck00018242493-20220419.htm
  HTML page:      https://secwatch.observer/filing/0001824293-22-000024

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer